A PHASE I SAFETY AND TOLERABILITY TRIAL OF RADIOTHERAPY, ANDROGEN DEPRIVATION, AND INTRATUMORAL INJECTIONS OF AdGVEGR.TNF.11D (TNFeradeTM) FOR PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCER.
Phase of Trial: Phase I
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Golnerminogene pradenovec (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors GenVec
- 08 Mar 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 22 Jan 2010 New trial record